188 related articles for article (PubMed ID: 37955745)
1. Neurodevelopment at 24 months corrected age in extremely preterm infants treated with dexamethasone alternatives during the late postnatal period: a cohort study.
Melan N; Pradat P; Godbert I; Pastor-Diez B; Basson E; Picaud JC
Eur J Pediatr; 2024 Feb; 183(2):677-687. PubMed ID: 37955745
[TBL] [Abstract][Full Text] [Related]
2. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
Doyle LW; Cheong JL; Ehrenkranz RA; Halliday HL
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001146. PubMed ID: 29063585
[TBL] [Abstract][Full Text] [Related]
3. [Glucocorticoide therapy in premature infants: French practices in 2006].
Autret-Leca E; Bauer S; Alberti C; Jonville-Béra AP; Aujard Y; Bensouda-Grimaldi L; Baud O
Arch Pediatr; 2009 Jul; 16(7):999-1004. PubMed ID: 19410441
[TBL] [Abstract][Full Text] [Related]
4. Hydrocortisone use in ventilated extremely preterm infants decreased bronchopulmonary dysplasia with no effects on neurodevelopment after two years.
Renault A; Patkaï J; Dassieu G; El Ayoubi M; Canouï-Poitrine F; Durrmeyer X
Acta Paediatr; 2016 Sep; 105(9):1047-55. PubMed ID: 27239054
[TBL] [Abstract][Full Text] [Related]
5. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
Doyle LW; Cheong JL; Ehrenkranz RA; Halliday HL
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001145. PubMed ID: 29063594
[TBL] [Abstract][Full Text] [Related]
6. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.
Halliday HL; Ehrenkranz RA; Doyle LW
Cochrane Database Syst Rev; 2010 Jan; (1):CD001146. PubMed ID: 20091516
[TBL] [Abstract][Full Text] [Related]
7. Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
Doyle LW; Cheong JL; Hay S; Manley BJ; Halliday HL
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD001145. PubMed ID: 34758507
[TBL] [Abstract][Full Text] [Related]
8. Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
Doyle LW; Cheong JL; Hay S; Manley BJ; Halliday HL
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD001146. PubMed ID: 34674229
[TBL] [Abstract][Full Text] [Related]
9. [The use of postnatal corticosteroid therapy in premature infants to prevent or treat bronchopulmonary dysplasia: current situation and recommendations].
Jarreau PH; Fayon M; Baud O; Autret-Leca E; Danan M; de Verdelhan A; Castot A
Arch Pediatr; 2010 Oct; 17(10):1480-7. PubMed ID: 20864322
[TBL] [Abstract][Full Text] [Related]
10. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.
Baud O; Maury L; Lebail F; Ramful D; El Moussawi F; Nicaise C; Zupan-Simunek V; Coursol A; Beuchée A; Bolot P; Andrini P; Mohamed D; Alberti C;
Lancet; 2016 Apr; 387(10030):1827-36. PubMed ID: 26916176
[TBL] [Abstract][Full Text] [Related]
11. Duration of mechanical ventilation is more critical for brain growth than postnatal hydrocortisone in extremely preterm infants.
Rousseau C; Guichard M; Saliba E; Morel B; Favrais G
Eur J Pediatr; 2021 Nov; 180(11):3307-3315. PubMed ID: 33993400
[TBL] [Abstract][Full Text] [Related]
12. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.
Halliday HL; Ehrenkranz RA; Doyle LW
Cochrane Database Syst Rev; 2009 Jan; (1):CD001146. PubMed ID: 19160190
[TBL] [Abstract][Full Text] [Related]
13. The Association of Dexamethasone and Hydrocortisone with Cerebellar Growth in Premature Infants.
Warmerdam LA; van Wezel-Meijler G; de Vries LS; Groenendaal F; Steggerda SJ
Neonatology; 2023; 120(5):615-623. PubMed ID: 37379806
[TBL] [Abstract][Full Text] [Related]
14. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age.
Baud O; Trousson C; Biran V; Leroy E; Mohamed D; Alberti C;
JAMA; 2017 Apr; 317(13):1329-1337. PubMed ID: 28384828
[TBL] [Abstract][Full Text] [Related]
15. Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018.
Bell EF; Hintz SR; Hansen NI; Bann CM; Wyckoff MH; DeMauro SB; Walsh MC; Vohr BR; Stoll BJ; Carlo WA; Van Meurs KP; Rysavy MA; Patel RM; Merhar SL; Sánchez PJ; Laptook AR; Hibbs AM; Cotten CM; D'Angio CT; Winter S; Fuller J; Das A;
JAMA; 2022 Jan; 327(3):248-263. PubMed ID: 35040888
[TBL] [Abstract][Full Text] [Related]
16. Randomized Trial of 42-Day Compared with 9-Day Courses of Dexamethasone for the Treatment of Evolving Bronchopulmonary Dysplasia in Extremely Preterm Infants.
Marr BL; Mettelman BB; Bode MM; Gross SJ
J Pediatr; 2019 Aug; 211():20-26.e1. PubMed ID: 31349916
[TBL] [Abstract][Full Text] [Related]
17. Postnatal steroids in extremely low birth weight infants: betamethasone or hydrocortisone?
Ben Said M; Hays S; Loys CM; Coletto L; Godbert I; Picaud JC
Acta Paediatr; 2013 Jul; 102(7):689-94. PubMed ID: 23551291
[TBL] [Abstract][Full Text] [Related]
18. Update on Postnatal Steroids.
Halliday HL
Neonatology; 2017; 111(4):415-422. PubMed ID: 28538237
[TBL] [Abstract][Full Text] [Related]
19. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.
Doyle LW; Ehrenkranz RA; Halliday HL
Cochrane Database Syst Rev; 2014 May; (5):CD001146. PubMed ID: 24825456
[TBL] [Abstract][Full Text] [Related]
20. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.
Watterberg KL; Walsh MC; Li L; Chawla S; D'Angio CT; Goldberg RN; Hintz SR; Laughon MM; Yoder BA; Kennedy KA; McDavid GE; Backstrom-Lacy C; Das A; Crawford MM; Keszler M; Sokol GM; Poindexter BB; Ambalavanan N; Hibbs AM; Truog WE; Schmidt B; Wyckoff MH; Khan AM; Garg M; Chess PR; Reynolds AM; Moallem M; Bell EF; Meyer LR; Patel RM; Van Meurs KP; Cotten CM; McGowan EC; Hines AC; Merhar S; Peralta-Carcelen M; Wilson-Costello DE; Kilbride HW; DeMauro SB; Heyne RJ; Mosquera RA; Natarajan G; Purdy IB; Lowe JR; Maitre NL; Harmon HM; Hogden LA; Adams-Chapman I; Winter S; Malcolm WF; Higgins RD;
N Engl J Med; 2022 Mar; 386(12):1121-1131. PubMed ID: 35320643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
